Meeting Banner
Abstract #4359

Perfusion MRI as the predictive/prognostic and Pharmacodynamic Biomarkers in Recurrent Malignant Glioma Treated with Bevacizumab: A Systematic Review and a time-to-event meta-analysis

Kyung Won Kim1, Sang Hyun Choi1, Seung Chai Jung1, Ja Youn Lee2, Ho Sung Kim1, and Seong Ho Park1

1Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of, 2National Evidence-based Healthcare Collaborating Agency, Seoul, Korea, Republic of

The current evidence in the literature shows that the rCBV of DSC-MRI is the most widely used perfusion MRI parameter. The rCBV can be used to predict disease progression and overall survival in patients with recurrent malignant glioma treated with BVZ. Various perfusion MRI parameters from DSC-MRI and DCE-MRI could play a role as pharmacodynamic biomarkers to evaluate the drug’s anti-angiogenic effect on tumor.

This abstract and the presentation materials are available to members only; a login is required.

Join Here